---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Pharmacodynamics"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Pharmacodynamics. Topics: Circulating insulin as a biomarker of exposure: healthy volunteers, Reduced insulin sensitivity after single infusions: healthy volunteers, Insulin biomarker response in congenital hyperinsulinism, Inhibition of IGF-2 signaling at the insulin receptor: in vitro studies, and 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Circulating insulin as a biomarker of exposure: healthy volunteers

> “Dose-dependent elevations of circulating insulin levels, likely related to reduced insulin clearance via monoclonal antibody action at receptors, represented a sensitive biomarker of X358 exposure.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-2.1.2.6.2-2"></a>

### Reduced insulin sensitivity after single infusions: healthy volunteers

> “X358-dependent increases in postprandial glucose levels and fasting homeostatic model assessment of insulin resistance values were observed and persisted for at least 1 week at the higher dose levels.”
> “In all the ITT cohorts, the slope for glucose lowering was substantially attenuated after X358 infusion of a similar magnitude, but with increasing duration with rising dose level.”
> “Single X358 infusions were well tolerated and resulted in a dose-dependent reduction in insulin sensitivity.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-2.1.2.6.2-3"></a>

### Insulin biomarker response in congenital hyperinsulinism

> “there was evidence of pharmacologic activity as target therapeutic drug concentrations were achieved in both treatment groups (5 mg/kg and 10 mg/kg) with highly sensitive biomarker responses (increases in circulating insulin) in the active treatment groups that are indicative of reduced insulin activity at its receptor.”
> “Notably, these responses were consistent with those of the Company’s Phase 2 RIZE study (see Figure 1).”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-2.1.2.6.2-4"></a>

### Inhibition of IGF-2 signaling at the insulin receptor: in vitro studies

> “To test this, the Company recently completed in vitro pharmacology studies to evaluate the impact of clinically relevant concentrations of RZ358 on insulin receptor activation by IGF-2, compared to insulin.”
> “These experiments successfully demonstrated the ability of RZ358 to similarly blunt both IGF-2 and insulin-mediated insulin-receptor signaling, at levels of these ligands that are disease-relevant in humans.”

Source: [Rezolute NICTH validation release (2024)](https://ir.rezolutebio.com/news/detail/327/rezolute-reports-validation-of-the-potential-use-of-rz358-for-treatment-of-non-islet-cell-tumor-hypoglycemia-nicth)

<a id="topic-2.1.2.6.2-5"></a>

### Reversal of insulin-induced hypoglycemia in mice: XMetD

> “Intraperitoneal injection of XMetD at 10 mg/kg twice weekly into normal mice induced insulin resistance.”
> “When sustained-release insulin implants were placed into normal mice, they developed fasting hypoglycemia in the range of 50 mg/dl.”
> “This hypoglycemia was reversed by XMetD treatment.”

Source: [Corbin et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3929448/)

<a id="topic-2.1.2.6.2-6"></a>

### Prevention of fasting hypoglycemia in a mouse model of KATP hyperinsulinism

> “SUR-1−/− and wild-type mice received twice weekly intraperitoneal injections of either XMetD or control antibody for 8 wks.”
> “Treatment with XMetD significantly decreased insulin sensitivity, and increased hepatic glucose output and fasting plasma glucose.”

Source: [Patel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6150619/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
